EA201792236A1 - Получение увеличенных в размере векторов на основе аденоассоциированного вируса - Google Patents
Получение увеличенных в размере векторов на основе аденоассоциированного вирусаInfo
- Publication number
- EA201792236A1 EA201792236A1 EA201792236A EA201792236A EA201792236A1 EA 201792236 A1 EA201792236 A1 EA 201792236A1 EA 201792236 A EA201792236 A EA 201792236A EA 201792236 A EA201792236 A EA 201792236A EA 201792236 A1 EA201792236 A1 EA 201792236A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- size
- aav
- associated virus
- vectors
- basis
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144862P | 2015-04-08 | 2015-04-08 | |
| US201562220067P | 2015-09-17 | 2015-09-17 | |
| PCT/US2016/026486 WO2016164609A2 (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201792236A1 true EA201792236A1 (ru) | 2018-03-30 |
Family
ID=56943906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792236A EA201792236A1 (ru) | 2015-04-08 | 2016-04-07 | Получение увеличенных в размере векторов на основе аденоассоциированного вируса |
Country Status (27)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2956477T2 (sl) | 2013-02-15 | 2024-05-31 | Bioverativ Therapeutics Inc. | Optimiran gen dejavnika VIII |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| TWI707951B (zh) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| IL257939B2 (en) | 2015-09-24 | 2023-03-01 | Biomarin Pharm Inc | Adeno-associated virus factor 8 vectors, associated virus particles, and medicinal formulations comprising the same |
| PT3411478T (pt) | 2016-02-01 | 2022-09-13 | Bioverativ Therapeutics Inc | Genes do fator viii otimizados |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| EP3655533A1 (en) | 2017-02-24 | 2020-05-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject |
| CN119491003A (zh) | 2017-05-05 | 2025-02-21 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| MA49153A (fr) * | 2017-05-19 | 2021-03-24 | Encoded Therapeutics Inc | Éléments régulateurs à haute activité |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
| TWI722310B (zh) | 2017-08-03 | 2021-03-21 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
| KR102780287B1 (ko) | 2017-08-09 | 2025-03-14 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| AU2018352236B2 (en) | 2017-10-16 | 2025-04-10 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| JP7401432B2 (ja) | 2017-12-01 | 2023-12-19 | エンコーデッド セラピューティクス， インコーポレイテッド | 操作されたｄｎａ結合タンパク質 |
| US12319929B2 (en) | 2018-05-15 | 2025-06-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| CA3106838A1 (en) * | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| BR112021002017A2 (pt) | 2018-08-09 | 2021-05-11 | Bioverativ Therapeutics Inc. | moléculas de ácido nucleico e usos das mesmas para terapia genética não viral |
| CA3114621A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN120349985A (zh) * | 2018-10-12 | 2025-07-22 | 建新公司 | 通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生 |
| CN114302968A (zh) * | 2019-08-29 | 2022-04-08 | 美国西门子医学诊断股份有限公司 | 用于检测aav脱落的试剂和方法 |
| JP2022549932A (ja) | 2019-09-30 | 2022-11-29 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| CN111218446B (zh) * | 2019-12-25 | 2023-03-28 | 劲帆生物医药科技（武汉）有限公司 | 一种肝脏特异性启动子及其应用 |
| IL296509A (en) * | 2020-03-16 | 2022-11-01 | Univ North Carolina Chapel Hill | Preparations and methods for selective detection of tumor-derived viral DNA |
| US12173307B2 (en) | 2020-06-24 | 2024-12-24 | Bioverativ Therapeutics Inc. | Methods for the purification of viral vectors |
| AU2021319208A1 (en) | 2020-07-30 | 2023-03-02 | Shape Therapeutics Inc. | Stable cell lines for inducible production of rAAV virions |
| CN116194152A (zh) | 2020-08-23 | 2023-05-30 | 比奥维拉迪维治疗股份有限公司 | 用于改进封闭端DNA（ceDNA）的产生的经修饰的杆状病毒系统 |
| AU2022332276A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| JP2024534123A (ja) | 2021-08-23 | 2024-09-18 | バイオベラティブ セラピューティクス インコーポレイテッド | バキュロウイルス発現システム |
| US20230091932A1 (en) | 2021-08-23 | 2023-03-23 | Bioverativ Therapeutics Inc. | Closed-end dna production with inverted terminal repeat sequences |
| KR20240067122A (ko) | 2021-09-30 | 2024-05-16 | 바이오버라티브 테라퓨틱스 인크. | 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산 |
| KR20240099288A (ko) | 2021-10-18 | 2024-06-28 | 리제너론 파마슈티칼스 인코포레이티드 | 아데노바이러스-연관 바이러스 폴리뉴클레오티드를 포함하는 진핵세포 |
| US20240392318A1 (en) * | 2023-04-26 | 2024-11-28 | Sanofi | Host cell lines and methods for identifying and using such host cell lines |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128780A0 (en) | 1996-09-06 | 2000-01-31 | Univ Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| JP2003511082A (ja) * | 1999-10-12 | 2003-03-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 第ｖｉｉｉ因子をコードするアデノ随伴ウィルスベクターとその使用法 |
| ES2505700T3 (es) | 2000-06-01 | 2014-10-10 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| ES2258601T3 (es) | 2001-11-13 | 2006-09-01 | The Trustees Of The University Of Pennsylvania | Un metodo para la identificacion de las secuencias desconocidas del virus adeno-asociado (vaa) y un kit para el metodo. |
| US20040092008A1 (en) * | 2002-11-12 | 2004-05-13 | Snyder Richard O. | Recombinant AAV vectors for gene therapy of hemophilia A |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| EP1625210B1 (en) | 2003-05-21 | 2010-12-01 | Genzyme Corporation | Methods for producing preparations of recombinant aav virions substantially free of empty capsids |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| ES2881050T3 (es) | 2009-06-16 | 2021-11-26 | Genzyme Corp | Métodos mejorados para la purificación de vectores de AAV recombinantes |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US9884071B2 (en) | 2011-02-17 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
| EP2911687B1 (en) * | 2012-10-26 | 2019-02-13 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| HUE050484T2 (hu) * | 2013-09-12 | 2020-12-28 | Biomarin Pharm Inc | VIII. faktort kódoló gént tartalmazó AAV vektorok |
| PE20170260A1 (es) | 2014-05-02 | 2017-04-12 | Genzyme Corp | Vectores de aav para la terapia genica de la retina y el snc |
| PL3256594T3 (pl) | 2015-02-10 | 2022-02-14 | Genzyme Corporation | Ulepszone dostarczanie cząstek wirusa do prążkowia i kory |
| TWI707951B (zh) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
-
2016
- 2016-04-06 TW TW105110751A patent/TWI707951B/zh active
- 2016-04-07 KR KR1020257027291A patent/KR20250126875A/ko active Pending
- 2016-04-07 CN CN201680033119.6A patent/CN107864657A/zh active Pending
- 2016-04-07 WO PCT/US2016/026486 patent/WO2016164609A2/en not_active Ceased
- 2016-04-07 IL IL283291A patent/IL283291B/en unknown
- 2016-04-07 CR CR20170505A patent/CR20170505A/es unknown
- 2016-04-07 MX MX2017012935A patent/MX2017012935A/es unknown
- 2016-04-07 PE PE2017001997A patent/PE20171800A1/es unknown
- 2016-04-07 BR BR112017021505A patent/BR112017021505A2/pt not_active Application Discontinuation
- 2016-04-07 SG SG11201708203UA patent/SG11201708203UA/en unknown
- 2016-04-07 HU HUE16767050A patent/HUE069779T2/hu unknown
- 2016-04-07 EP EP24207442.5A patent/EP4512429A3/en active Pending
- 2016-04-07 CA CA2982123A patent/CA2982123A1/en active Pending
- 2016-04-07 IL IL294965A patent/IL294965A/en unknown
- 2016-04-07 KR KR1020177032062A patent/KR102848324B1/ko active Active
- 2016-04-07 US US15/565,020 patent/US10815497B2/en active Active
- 2016-04-07 JP JP2017553005A patent/JP6878299B2/ja active Active
- 2016-04-07 ES ES16767050T patent/ES3008382T3/es active Active
- 2016-04-07 DK DK16767050.4T patent/DK3280799T3/da active
- 2016-04-07 EP EP16767050.4A patent/EP3280799B1/en active Active
- 2016-04-07 SG SG10201912912QA patent/SG10201912912QA/en unknown
- 2016-04-07 SG SG10201909381W patent/SG10201909381WA/en unknown
- 2016-04-07 EA EA201792236A patent/EA201792236A1/ru unknown
- 2016-04-07 AU AU2016245806A patent/AU2016245806A1/en not_active Abandoned
- 2016-04-07 PL PL16767050.4T patent/PL3280799T3/pl unknown
- 2016-04-07 TN TNP/2017/000431A patent/TN2017000431A1/en unknown
- 2016-04-08 UY UY0001036611A patent/UY36611A/es not_active Application Discontinuation
-
2017
- 2017-10-06 PH PH12017501836A patent/PH12017501836A1/en unknown
- 2017-10-06 GT GT201700214A patent/GT201700214A/es unknown
- 2017-10-06 CL CL2017002537A patent/CL2017002537A1/es unknown
- 2017-10-08 IL IL254933A patent/IL254933B/en active IP Right Grant
- 2017-11-03 CO CONC2017/0011344A patent/CO2017011344A2/es unknown
- 2017-11-08 EC ECIEPI201774016A patent/ECSP17074016A/es unknown
-
2021
- 2021-04-28 JP JP2021075526A patent/JP2021118724A/ja not_active Withdrawn
-
2022
- 2022-06-07 AU AU2022203942A patent/AU2022203942B2/en active Active
-
2023
- 2023-06-14 JP JP2023097370A patent/JP2023116678A/ja active Pending
-
2024
- 2024-03-12 AU AU2024201619A patent/AU2024201619A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792236A1 (ru) | Получение увеличенных в размере векторов на основе аденоассоциированного вируса | |
| MX2019013172A (es) | Composiciones y metodos para tratar la enfermedad de huntington. | |
| PH12019500068A1 (en) | Novel adeno-associated virus capsid proteins | |
| MX2020005282A (es) | Vector para la produccion de particulas aav. | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
| AU2018260998A2 (en) | Modulatory polynucleotides | |
| MX2018012663A (es) | Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus. | |
| CL2018000170A1 (es) | Vectores de aav para la terapia génica de la retina y el snc (divisional de solicitud 201602713) | |
| MX2016009965A (es) | Produccion de alta titulacion de vectores virales adenoasociados. | |
| EA202190512A1 (ru) | Композиции и способы для производства векторов для генной терапии | |
| MX2017006216A (es) | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MY195391A (en) | Column-Based Fully Scalable Raav Manufacturing Process | |
| EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
| PT3488007T (pt) | Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos | |
| MY190926A (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| MX2025008949A (es) | Arni variante | |
| MX2020002148A (es) | Vectores adenoasociados recombinantes. | |
| MX2018007330A (es) | Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii. | |
| MA41387B1 (fr) | Production de vecteurs adéno-associés surdimensionnés | |
| NZ764033A (en) | Aav vectors for retinal and cns gene therapy |